Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Key Points

• To assess patient-reported outcomes and quality of life in patients with advanced breast cancer receiving treatments in the EMBER-3 trial.
• Conducted a phase III trial comparing treatment arms
• Included qualitative interviews and patient-reported outcomes
• Evaluated quality of life metrics across treatment groups
• Patient-reported outcomes and quality of life were maintained across treatment arms
• Higher incidence of diarrhea was noted in the imlunestrant-abemaciclib group
• Findings support a favorable risk-benefit profile for imlunestrant therapy

Abstract